mardi 1 mars 2016

Onco Actu du 1er mars 2016

3.6 Prévention - Activité physique

Sloan Kettering's Quest to Prove Exercise Can Inhibit Cancer [Wall Street Journal]

4. Dépistage, diagnostic et pronostic

Scientists develop new way to view bone cancer [The Institute of Cancer Research]

New Device Lights Up Cancer Surgery [MIT Technology Review]

4.1 Dép., diag. & prono. - Prostate

Is metastatic prostate cancer tailor-made for precision oncology? [Fred Hutch]

More prostate patients being monitored instead of undergoing immediate treatment: report [The Globe and Mail]

4.12 Biopsies liquides

Metabolic Phenotyping of Blood Plasma Allows for the Detection of Lung Cancer [IASLC]

5. Traitements

A New Chemotherapy Idea [In the Pipeline]

There’s a real sense of optimism around new ways of tackling lung cancer [Cancer Research UK]

5.10 Traitements - Essais

Publishing all trial results: a covenant with patients [The Cancer Blog]

5.12 Immunothérapies

Adding Immunotherapy to RFA May Benefit Colorectal Cancer Patients With Liver Metastasis [AACR]

5.12.2 Immunothérapies - CAR-T

Baxalta dives into CAR-T with a $1.6B bet [FierceBiotech]

5.2 Pharma

Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma [BMS]

European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung [Boehringer Ingelheim]

Japanese MHLW Grants Orphan Drug Designation in Japan to Takeda's Oral Proteasome Inhibitor Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma [Takeda]

AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) [AbbVie]

Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab [Peregrine]

AstraZeneca cancer drug fails in mesothelioma trial [Reuters]

5.2.1 Pharma - Partenariats

Boehringer and AbbVie are reportedly weighing a multibillion-dollar cancer alliance [FierceBiotech]

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug [Xconomy]

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan [Ipsen]

5.3 Traitements - FDA, EMA,...

Improving patient safety through more proactive risk management [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma [Genentech]

FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET) [Novartis]

New treatment for advanced form of kidney cancer [EMA]

5.4 Traitements - Economie

Push for Keytruda funding – Expert reaction [Science Media Centre]

Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says [NY Times]

6.10 Politiques

Precision Medicine at one year: A soaring White House summit and the potholes ahead [HealthNewsReview]

Five Reasons To Be Optimistic About The Precision Medicine Initiative [Forbes]

6.5 Médecines alternatives

Sh*t naturopaths say, part 4: Naturopathic oncology versus science [Respectful Insolence]

6.7 DMP, Big Data & applis

ASCO Pledges to U.S. Department of Health and Human Services (HHS) to Improve Health Information Sharing Between Consumers and Health Care Providers [ASCO]